Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites
: Background: Advanced Hodgkin's lymphoma (HL) is curable by conventional chemotherapy in 60–70% of patients. The pretreatment identification of a sizeable subgroup of patients with sufficiently low failure‐free survival (FFS) to be eligible for investigational treatment is necessary. Objective...
Gespeichert in:
| Veröffentlicht in: | European journal of haematology 2001-11, Vol.67 (5-6), p.279-288 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 288 |
|---|---|
| container_issue | 5-6 |
| container_start_page | 279 |
| container_title | European journal of haematology |
| container_volume | 67 |
| creator | Vassilakopoulos, T.P. Angelopoulou, M.K. Siakantaris, M.P. Kontopidou, F.N. Dimopoulou, M.N. Barbounis, A. Grigorakis, V. Karkantaris, C. Anargyrou, K. Chatziioannou, M. Rombos, J. Boussiotis, V.A. Vaiopoulos, G. Kittas, C. Pangalis, G.A. |
| description | : Background: Advanced Hodgkin's lymphoma (HL) is curable by conventional chemotherapy in 60–70% of patients. The pretreatment identification of a sizeable subgroup of patients with sufficiently low failure‐free survival (FFS) to be eligible for investigational treatment is necessary. Objectives: To determine the prognostic significance of the number of involved sites (NIS) in patients with advanced HL and its relationship to the International Prognostic Score (IPS). Methods: A retrospective review of patients with advanced HL, defined as Ann Arbor stage (AAS) IB, IIB, III or IV, treated with anthracycline‐based regimens. The end‐point was FFS. Results: We identified 277 patients with a median age of 32 yr (14–78), 57% of whom were males. AAS was I in 4% of patients, II in 29%, III in 38% and IV in 29%. B‐symptoms were recorded in 81%. Most patients had nodular sclerosis (64%) and mixed cellularity (26%) histology. IPS was ≥3 in 44% of 242 evaluable patients. The NIS was ≥5 in 32% of the patients and 20% of all patients had both ≥5 involved sites and IPS ≥3. The 10‐yr FFS was 67%, being 76% vs. 50% for patients with ≤4 vs. ≥5 involved sites (P |
| doi_str_mv | 10.1034/j.1600-0609.2001.00561.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71264726</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71264726</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4321-1007364484ef04d4490e5eeb338ec5378e3e2d94a6958de4be31122a040137553</originalsourceid><addsrcrecordid>eNqNkF1v0zAUhi3ExMrgLyDfAFfJjj8SJ4ibaRorbIIKDe3ScpOTzl0SFzvt2n8_Z622213ZPn7ec44eQiiDlIGQp8uU5QAJ5FCmHIClAFnO0u0bMnn-eEsmUAJPpJTsmLwPYQkAvGTqHTlmrFAcVDYhfubdondhsBVtTDU4H6jtqak3pq-wpmEwC6RTVy_ubf810HbXre5cZ77R4Q5psIveNrYaWeqap1q_7ubox5ftN67dxCamN4Pr4oRgBwwfyFFj2oAfD-cJ-ffj4uZ8mlz_ufx5fnadVFJwljAAJXIpC4kNyFrKEjBDnAtRYJUJVaBAXpfS5GVW1CjnKBjj3IAEJlSWiRPyZd935d3_NYZBdzZU2LamR7cOWjGeS8XzCBZ7sPIuBI-NXnnbGb_TDPToWy_1qFWPWvXoWz_51tsY_XSYsZ53WL8ED4Ij8PkAmFCZtvFRlQ0vnJAZlyWL3Pc992Bb3L16AX3xaxovMZ7s4zYMuH2OG3-vcxVt6Nvfl1rNcjG7_Xujr8QjdGaqHA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71264726</pqid></control><display><type>article</type><title>Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Vassilakopoulos, T.P. ; Angelopoulou, M.K. ; Siakantaris, M.P. ; Kontopidou, F.N. ; Dimopoulou, M.N. ; Barbounis, A. ; Grigorakis, V. ; Karkantaris, C. ; Anargyrou, K. ; Chatziioannou, M. ; Rombos, J. ; Boussiotis, V.A. ; Vaiopoulos, G. ; Kittas, C. ; Pangalis, G.A.</creator><creatorcontrib>Vassilakopoulos, T.P. ; Angelopoulou, M.K. ; Siakantaris, M.P. ; Kontopidou, F.N. ; Dimopoulou, M.N. ; Barbounis, A. ; Grigorakis, V. ; Karkantaris, C. ; Anargyrou, K. ; Chatziioannou, M. ; Rombos, J. ; Boussiotis, V.A. ; Vaiopoulos, G. ; Kittas, C. ; Pangalis, G.A.</creatorcontrib><description>: Background: Advanced Hodgkin's lymphoma (HL) is curable by conventional chemotherapy in 60–70% of patients. The pretreatment identification of a sizeable subgroup of patients with sufficiently low failure‐free survival (FFS) to be eligible for investigational treatment is necessary. Objectives: To determine the prognostic significance of the number of involved sites (NIS) in patients with advanced HL and its relationship to the International Prognostic Score (IPS). Methods: A retrospective review of patients with advanced HL, defined as Ann Arbor stage (AAS) IB, IIB, III or IV, treated with anthracycline‐based regimens. The end‐point was FFS. Results: We identified 277 patients with a median age of 32 yr (14–78), 57% of whom were males. AAS was I in 4% of patients, II in 29%, III in 38% and IV in 29%. B‐symptoms were recorded in 81%. Most patients had nodular sclerosis (64%) and mixed cellularity (26%) histology. IPS was ≥3 in 44% of 242 evaluable patients. The NIS was ≥5 in 32% of the patients and 20% of all patients had both ≥5 involved sites and IPS ≥3. The 10‐yr FFS was 67%, being 76% vs. 50% for patients with ≤4 vs. ≥5 involved sites (P < 0.0001). The NIS (≥ 5), AAS IV and anemia were independent predictors of FFS in multivariate analysis. The NIS remained significant along with IPS, when the latter was included in the analysis. Patients with ≥5 involved sites and IPS ≥3 had 10‐yr FFS overall, and relapse‐free survival of 41%, 45% and 49%, respectively. Conclusions: The NIS was associated with FFS in advanced HL, was independent of IPS, and led to the identification of a sizeable subgroup of patients with 10‐yr FFS of approximately 40%. This factor should be evaluated during the development of prognostic systems.</description><identifier>ISSN: 0902-4441</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1034/j.1600-0609.2001.00561.x</identifier><identifier>PMID: 11872075</identifier><identifier>CODEN: EJHAEC</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science, Ltd</publisher><subject>Adolescent ; Adult ; advance stage ; Aged ; Antibiotics, Antineoplastic - therapeutic use ; Biological and medical sciences ; Disease-Free Survival ; Female ; Hematologic and hematopoietic diseases ; Hodgkin Disease - drug therapy ; Hodgkin Disease - pathology ; Hodgkin's lymphoma ; Humans ; International Prognostic Score ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; number of involved sites ; Predictive Value of Tests ; Prognosis ; prognostic factors ; Retrospective Studies</subject><ispartof>European journal of haematology, 2001-11, Vol.67 (5-6), p.279-288</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4321-1007364484ef04d4490e5eeb338ec5378e3e2d94a6958de4be31122a040137553</citedby><cites>FETCH-LOGICAL-c4321-1007364484ef04d4490e5eeb338ec5378e3e2d94a6958de4be31122a040137553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1034%2Fj.1600-0609.2001.00561.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1034%2Fj.1600-0609.2001.00561.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13452491$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11872075$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vassilakopoulos, T.P.</creatorcontrib><creatorcontrib>Angelopoulou, M.K.</creatorcontrib><creatorcontrib>Siakantaris, M.P.</creatorcontrib><creatorcontrib>Kontopidou, F.N.</creatorcontrib><creatorcontrib>Dimopoulou, M.N.</creatorcontrib><creatorcontrib>Barbounis, A.</creatorcontrib><creatorcontrib>Grigorakis, V.</creatorcontrib><creatorcontrib>Karkantaris, C.</creatorcontrib><creatorcontrib>Anargyrou, K.</creatorcontrib><creatorcontrib>Chatziioannou, M.</creatorcontrib><creatorcontrib>Rombos, J.</creatorcontrib><creatorcontrib>Boussiotis, V.A.</creatorcontrib><creatorcontrib>Vaiopoulos, G.</creatorcontrib><creatorcontrib>Kittas, C.</creatorcontrib><creatorcontrib>Pangalis, G.A.</creatorcontrib><title>Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites</title><title>European journal of haematology</title><addtitle>Eur J Haematol</addtitle><description>: Background: Advanced Hodgkin's lymphoma (HL) is curable by conventional chemotherapy in 60–70% of patients. The pretreatment identification of a sizeable subgroup of patients with sufficiently low failure‐free survival (FFS) to be eligible for investigational treatment is necessary. Objectives: To determine the prognostic significance of the number of involved sites (NIS) in patients with advanced HL and its relationship to the International Prognostic Score (IPS). Methods: A retrospective review of patients with advanced HL, defined as Ann Arbor stage (AAS) IB, IIB, III or IV, treated with anthracycline‐based regimens. The end‐point was FFS. Results: We identified 277 patients with a median age of 32 yr (14–78), 57% of whom were males. AAS was I in 4% of patients, II in 29%, III in 38% and IV in 29%. B‐symptoms were recorded in 81%. Most patients had nodular sclerosis (64%) and mixed cellularity (26%) histology. IPS was ≥3 in 44% of 242 evaluable patients. The NIS was ≥5 in 32% of the patients and 20% of all patients had both ≥5 involved sites and IPS ≥3. The 10‐yr FFS was 67%, being 76% vs. 50% for patients with ≤4 vs. ≥5 involved sites (P < 0.0001). The NIS (≥ 5), AAS IV and anemia were independent predictors of FFS in multivariate analysis. The NIS remained significant along with IPS, when the latter was included in the analysis. Patients with ≥5 involved sites and IPS ≥3 had 10‐yr FFS overall, and relapse‐free survival of 41%, 45% and 49%, respectively. Conclusions: The NIS was associated with FFS in advanced HL, was independent of IPS, and led to the identification of a sizeable subgroup of patients with 10‐yr FFS of approximately 40%. This factor should be evaluated during the development of prognostic systems.</description><subject>Adolescent</subject><subject>Adult</subject><subject>advance stage</subject><subject>Aged</subject><subject>Antibiotics, Antineoplastic - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hodgkin Disease - drug therapy</subject><subject>Hodgkin Disease - pathology</subject><subject>Hodgkin's lymphoma</subject><subject>Humans</subject><subject>International Prognostic Score</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Staging</subject><subject>number of involved sites</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>prognostic factors</subject><subject>Retrospective Studies</subject><issn>0902-4441</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkF1v0zAUhi3ExMrgLyDfAFfJjj8SJ4ibaRorbIIKDe3ScpOTzl0SFzvt2n8_Z622213ZPn7ec44eQiiDlIGQp8uU5QAJ5FCmHIClAFnO0u0bMnn-eEsmUAJPpJTsmLwPYQkAvGTqHTlmrFAcVDYhfubdondhsBVtTDU4H6jtqak3pq-wpmEwC6RTVy_ubf810HbXre5cZ77R4Q5psIveNrYaWeqap1q_7ubox5ftN67dxCamN4Pr4oRgBwwfyFFj2oAfD-cJ-ffj4uZ8mlz_ufx5fnadVFJwljAAJXIpC4kNyFrKEjBDnAtRYJUJVaBAXpfS5GVW1CjnKBjj3IAEJlSWiRPyZd935d3_NYZBdzZU2LamR7cOWjGeS8XzCBZ7sPIuBI-NXnnbGb_TDPToWy_1qFWPWvXoWz_51tsY_XSYsZ53WL8ED4Ij8PkAmFCZtvFRlQ0vnJAZlyWL3Pc992Bb3L16AX3xaxovMZ7s4zYMuH2OG3-vcxVt6Nvfl1rNcjG7_Xujr8QjdGaqHA</recordid><startdate>200111</startdate><enddate>200111</enddate><creator>Vassilakopoulos, T.P.</creator><creator>Angelopoulou, M.K.</creator><creator>Siakantaris, M.P.</creator><creator>Kontopidou, F.N.</creator><creator>Dimopoulou, M.N.</creator><creator>Barbounis, A.</creator><creator>Grigorakis, V.</creator><creator>Karkantaris, C.</creator><creator>Anargyrou, K.</creator><creator>Chatziioannou, M.</creator><creator>Rombos, J.</creator><creator>Boussiotis, V.A.</creator><creator>Vaiopoulos, G.</creator><creator>Kittas, C.</creator><creator>Pangalis, G.A.</creator><general>Blackwell Science, Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200111</creationdate><title>Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites</title><author>Vassilakopoulos, T.P. ; Angelopoulou, M.K. ; Siakantaris, M.P. ; Kontopidou, F.N. ; Dimopoulou, M.N. ; Barbounis, A. ; Grigorakis, V. ; Karkantaris, C. ; Anargyrou, K. ; Chatziioannou, M. ; Rombos, J. ; Boussiotis, V.A. ; Vaiopoulos, G. ; Kittas, C. ; Pangalis, G.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4321-1007364484ef04d4490e5eeb338ec5378e3e2d94a6958de4be31122a040137553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>advance stage</topic><topic>Aged</topic><topic>Antibiotics, Antineoplastic - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hodgkin Disease - drug therapy</topic><topic>Hodgkin Disease - pathology</topic><topic>Hodgkin's lymphoma</topic><topic>Humans</topic><topic>International Prognostic Score</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Staging</topic><topic>number of involved sites</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>prognostic factors</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vassilakopoulos, T.P.</creatorcontrib><creatorcontrib>Angelopoulou, M.K.</creatorcontrib><creatorcontrib>Siakantaris, M.P.</creatorcontrib><creatorcontrib>Kontopidou, F.N.</creatorcontrib><creatorcontrib>Dimopoulou, M.N.</creatorcontrib><creatorcontrib>Barbounis, A.</creatorcontrib><creatorcontrib>Grigorakis, V.</creatorcontrib><creatorcontrib>Karkantaris, C.</creatorcontrib><creatorcontrib>Anargyrou, K.</creatorcontrib><creatorcontrib>Chatziioannou, M.</creatorcontrib><creatorcontrib>Rombos, J.</creatorcontrib><creatorcontrib>Boussiotis, V.A.</creatorcontrib><creatorcontrib>Vaiopoulos, G.</creatorcontrib><creatorcontrib>Kittas, C.</creatorcontrib><creatorcontrib>Pangalis, G.A.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vassilakopoulos, T.P.</au><au>Angelopoulou, M.K.</au><au>Siakantaris, M.P.</au><au>Kontopidou, F.N.</au><au>Dimopoulou, M.N.</au><au>Barbounis, A.</au><au>Grigorakis, V.</au><au>Karkantaris, C.</au><au>Anargyrou, K.</au><au>Chatziioannou, M.</au><au>Rombos, J.</au><au>Boussiotis, V.A.</au><au>Vaiopoulos, G.</au><au>Kittas, C.</au><au>Pangalis, G.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites</atitle><jtitle>European journal of haematology</jtitle><addtitle>Eur J Haematol</addtitle><date>2001-11</date><risdate>2001</risdate><volume>67</volume><issue>5-6</issue><spage>279</spage><epage>288</epage><pages>279-288</pages><issn>0902-4441</issn><eissn>1600-0609</eissn><coden>EJHAEC</coden><abstract>: Background: Advanced Hodgkin's lymphoma (HL) is curable by conventional chemotherapy in 60–70% of patients. The pretreatment identification of a sizeable subgroup of patients with sufficiently low failure‐free survival (FFS) to be eligible for investigational treatment is necessary. Objectives: To determine the prognostic significance of the number of involved sites (NIS) in patients with advanced HL and its relationship to the International Prognostic Score (IPS). Methods: A retrospective review of patients with advanced HL, defined as Ann Arbor stage (AAS) IB, IIB, III or IV, treated with anthracycline‐based regimens. The end‐point was FFS. Results: We identified 277 patients with a median age of 32 yr (14–78), 57% of whom were males. AAS was I in 4% of patients, II in 29%, III in 38% and IV in 29%. B‐symptoms were recorded in 81%. Most patients had nodular sclerosis (64%) and mixed cellularity (26%) histology. IPS was ≥3 in 44% of 242 evaluable patients. The NIS was ≥5 in 32% of the patients and 20% of all patients had both ≥5 involved sites and IPS ≥3. The 10‐yr FFS was 67%, being 76% vs. 50% for patients with ≤4 vs. ≥5 involved sites (P < 0.0001). The NIS (≥ 5), AAS IV and anemia were independent predictors of FFS in multivariate analysis. The NIS remained significant along with IPS, when the latter was included in the analysis. Patients with ≥5 involved sites and IPS ≥3 had 10‐yr FFS overall, and relapse‐free survival of 41%, 45% and 49%, respectively. Conclusions: The NIS was associated with FFS in advanced HL, was independent of IPS, and led to the identification of a sizeable subgroup of patients with 10‐yr FFS of approximately 40%. This factor should be evaluated during the development of prognostic systems.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science, Ltd</pub><pmid>11872075</pmid><doi>10.1034/j.1600-0609.2001.00561.x</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-4441 |
| ispartof | European journal of haematology, 2001-11, Vol.67 (5-6), p.279-288 |
| issn | 0902-4441 1600-0609 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71264726 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adolescent Adult advance stage Aged Antibiotics, Antineoplastic - therapeutic use Biological and medical sciences Disease-Free Survival Female Hematologic and hematopoietic diseases Hodgkin Disease - drug therapy Hodgkin Disease - pathology Hodgkin's lymphoma Humans International Prognostic Score Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Multivariate Analysis Neoplasm Staging number of involved sites Predictive Value of Tests Prognosis prognostic factors Retrospective Studies |
| title | Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T02%3A12%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20factors%20in%20advanced%20stage%20Hodgkin's%20lymphoma:%20the%20significance%20of%20the%20number%20of%20involved%20anatomic%20sites&rft.jtitle=European%20journal%20of%20haematology&rft.au=Vassilakopoulos,%20T.P.&rft.date=2001-11&rft.volume=67&rft.issue=5-6&rft.spage=279&rft.epage=288&rft.pages=279-288&rft.issn=0902-4441&rft.eissn=1600-0609&rft.coden=EJHAEC&rft_id=info:doi/10.1034/j.1600-0609.2001.00561.x&rft_dat=%3Cproquest_cross%3E71264726%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71264726&rft_id=info:pmid/11872075&rfr_iscdi=true |